Billion-Dollar Contracts, Takeover Battle and 600% Upside Potential: Where the Action Is Now - Frasers Group, Hugo Boss, MustGrow Biologics, OHB

Hugo Boss Shares Rise: Frasers Seeks Majority Control – Is a Higher Takeover Premium Now on the Table?

Hugo Boss shares (WKN: A1PHFF | ISIN: DE000A1PHFF7 | Ticker: BOSS) have risen by a good % since the start of the week to a latest price of EUR 38.50. Since the start of the year, the fashion group has thus recorded a price gain of 6.0%. New takeover speculation could now add to the excitement. This follows an announcement by the major British shareholder, Frasers Group (WKN: A0MK5S | ISIN: GB00B1QH8P22 | Ticker symbol: ZVX). Following the completion of its voluntary takeover bid, the company already holds 47.89% of Hugo Boss shares and intends to increase its stake to more than 50%. However, Frasers left open whether, when and at what price further shares would be purchased.

This means the British retail group is now just 2.11 percentage points short of an absolute majority. Frasers had previously offered Hugo Boss shareholders EUR 38 per share. The fashion group's Executive Board and Supervisory Board unanimously deemed this price to be financially inappropriate and recommended rejecting the offer. Nevertheless, 17.62% of the share capital was tendered. A stake of more than 50% would give Frasers considerable influence over ordinary Annual General Meeting resolutions. However, this would not yet enable it to gain full control or exclude minority shareholders. Nor does exceeding the 50% threshold automatically trigger a new public takeover bid. In addition, Frasers is currently assessing whether to continue supporting Supervisory Board Chairman Stephan Sturm.

Operationally, Hugo Boss remains in a difficult phase. In the second quarter, currency-adjusted turnover fell by 9% to EUR 905 million. The Europe, Middle East and Africa (EMEA) region performed particularly poorly, with a 13% decline. Operating profit fell to EUR 94 million in the first half of the year. By contrast, profitability and cash flow showed a positive trend. The gross margin rose by 2 percentage points to 64.9% in the second quarter. At the same time, inventories were reduced by 15%. Free cash flow before lease payments reached EUR 137 million in the first half of the year.

For 2026, management continues to expect a decline in turnover in the mid- to high-single-digit range and EBIT between EUR 300 and 350 million. Analysts remain largely cautious: as of mid-August, there was 1 "Buy" recommendation, 14 "Hold" recommendations and 2 "Sell" recommendations. The average price target of EUR 38.81 was just below the current share price.

From a technical analysis perspective, the picture has brightened recently. Trading at EUR 39.02, the share price is above the key moving averages, which provide an important support zone between EUR 36.8 and 38.1. The next resistance zone is between EUR 39.50 and 40.50. For investors, the situation remains two-sided: further purchases by Frasers could underpin the share price and trigger fresh speculation about a higher price. However, no such offer has been announced as yet. It will therefore be crucial to see whether Hugo Boss can also achieve an operational turnaround and whether the share price can sustainably break through the resistance level at EUR 40.50.

MustGrow Biologics: Partnership with Bayer Delivers First Profit

The investment story of MustGrow Biologics, a company still relatively unknown in Germany, is steadily gaining momentum against the backdrop of increasingly stringent environmental regulations and the clear trend towards regenerative agriculture. The Canadian biotech company is responding to global pressure from consumers and policymakers to reduce the use of chemical active ingredients in agriculture by developing innovative organic agricultural products derived from mustard seeds. The main focus of operational scaling in 2026 is on the already-approved organic biofertility product TerraSante™, which is being rolled out gradually in various US states including California, Washington and Florida. These states offer extensive acreage dedicated to high-value crops, meaning that soil-improving effects and optimized nutrient management become economically measurable particularly quickly for farmers once the product is applied.

Financially, the second quarter of 2026 marks a historic turning point, as MustGrow has achieved profitability. In Germany, the first development milestone payment of CAD 1.4 million from the German agricultural group Bayer AG attracted significant attention. As a result, the company achieved a net profit of CAD 0.30 million. This was offset by direct product sales from TerraSante™ totaling CAD 75,000, highlighting the still-early stage of market penetration. According to MustGrow's estimates, Bayer could invest an estimated USD 35 to 40 million over the next 5 to 7 years to advance the approval and commercialization of the pre-registered mustard-derived biocontrol product TerraMG™. This partnership scientifically validates the technology and, in addition to providing MustGrow with a high degree of financial predictability, also secures the sales strength of the globally active group.

In order to fully meet the high customer demand for TerraSante™ and to compensate for temporary bottlenecks at contract manufacturers, the management has recently strengthened the capital base. A heavily oversubscribed capital raise generated around CAD 3.7 million, whilst the original target had been an inflow of just CAD 2.0 million. The new shares were placed at CAD 0.50 per share, plus a call option at CAD 0.70. The fresh cash will flow directly into building up inventory and into working capital. A research report by the analysis firm GBC supports this growth narrative with a clear "Buy" recommendation and a target price of EUR 1.66 by 31 December 2027, which, based on the current share price of EUR 0.25, represents a calculated upside potential of a spectacular 664%.

OHB Stock Plunges Nearly 9% Despite Billion-Euro Order: Is the Space Rally Finally Over?

The OHB share (WKN: 593612 | ISIN: DE0005936124 | Ticker: OHB) was among the biggest losers on the German stock market on Tuesday this week. The share closed 8.% lower at EUR 184.80 and only stabilized on Wednesday at EUR 181.80. Its market capitalization stands at around EUR 3.8 billion. Despite the recent slump, it is still up by around 56% since the start of the year and by approximately 180% over a 52-week period. The timing of the sell-off is noteworthy. As recently as Monday, OHB announced a contract worth just under EUR 1 billion from the Luxembourg-based satellite operator SES. OHB is to develop and build 18 satellite platforms for the European communications system IRIS². This is the first major contract under the EU program designed to strengthen Western Europe's independence in secure satellite communications.

However, the positive news failed to stabilize the share price. No specific negative corporate trigger for the slump was apparent. The decline therefore points primarily to profit-taking, high valuation expectations and technical selling. Furthermore, despite the increase in the free float, only a limited proportion of the shares are freely tradable, which can cause price movements to be particularly volatile.

Operationally, OHB posted growth in the first half of the year. Total revenue rose by 11% to EUR 627.9 million and adjusted EBITDA by 31% to EUR 60.4 million. However, the picture was different for net profit: in the first quarter of 2026, OHB still reported a profit of EUR 9.9 million. In the second quarter, by contrast, a loss attributable to shareholders of EUR 5.1 million was recorded, having made a profit of EUR 7.1 million in the same quarter of the previous year. This resulted in a profit of EUR 4.8 million for the first half of 2026. For 2026, management confirmed total revenue of around EUR 1.4 billion and an adjusted EBITDA margin of between 10.5% and 11%. The order book already stood at EUR 3.3 billion at the end of June. The fundamental growth story therefore remains essentially intact, but following the previous surge in the share price, very high expectations have long since been priced in.

From a technical analysis perspective, the picture has deteriorated significantly. The recovery faltered several times in mid-August in the range between EUR 265 and EUR 280. Subsequently, the support levels at EUR 250 and EUR 230 were breached. At EUR 181.8, the share is trading well below the 20-day moving average of EUR 225.9 and the 200-day moving average of EUR 251.4. An initial potential support zone now lies between EUR 169.5 and EUR 175. If the share price falls below this range as well, the price gap between EUR 146.2 and EUR 155.4 could come into focus. On the upside, OHB would first need to reclaim the EUR 200 mark, then the EUR 225–230 range, to improve the short-term outlook.

For investors, OHB therefore represents a gamble between strong growth prospects and a clearly weakened chart. The multi-billion-dollar order bolsters the long-term outlook but is not currently triggering a new rally. The decisive factor will be whether the zone around EUR 175 holds or whether the sell-off continues despite full order books.

Although the fashion group Hugo Boss is going through a difficult operational period, the plan by its major shareholder, Frasers, to take a majority stake is fuelling renewed optimism on the stock market. Thanks to a milestone payment from its partnership with Bayer, the Canadian biotech company MustGrow Biologics is in the black for the first time and is now planning to expand its production to meet excess demand. Despite a major new satellite contract worth around EUR 1 billion, the shares of the aerospace group OHB are suffering from profit-taking and a gloomy technical picture.